EMERGENT BIOSOLUTIONS INC. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
EMERGENT BIOSOLUTIONS INC. (EBS) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$26.00 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-08.
Discontinued › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2019-05-08
- EMERGENT BIOSOLUTIONS INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2019-03-31 was -$26.00M.
- EMERGENT BIOSOLUTIONS INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2018-12-31 was -$3.48M, a 110.25% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2018-09-30 was $20.95M, a 37.57% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2018-06-30 was $50.14M, a 986.14% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2018 was $62.70M, a 24.09% decline from fiscal 2017.
- EMERGENT BIOSOLUTIONS INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2017 was $82.60M, a 59.46% increase from fiscal 2016.
- EMERGENT BIOSOLUTIONS INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2016 was $51.80M, a 17.61% decline from fiscal 2015.
- EMERGENT BIOSOLUTIONS INC. net income (loss), including portion attributable to noncontrolling interest for fiscal 2015 was $62.87M, a 71.12% increase from fiscal 2014.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|
| 2019-03-31 | -$26.00M 10-Q · filed 2019-05-08 | -$29.48M derived: sum of 2 quarters · filed 2019-05-08 | -$8.54M derived: sum of 3 quarters · filed 2019-05-08 | $41.60M derived: sum of 4 quarters · filed 2019-05-08 | ||
| 2018-12-31 | -$3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $17.46M derived: sum of 2 quarters · filed 2019-02-22 | $67.60M derived: sum of 3 quarters · filed 2019-02-22 | $62.70M 10-K · filed 2019-02-22 | ||
| 2018-09-30 | $20.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | $71.08M derived: sum of 2 quarters · filed 2018-11-02 | $66.18M 10-Q · filed 2018-11-02 | $100.13M derived: sum of 4 quarters · filed 2019-05-08 | ||
| 2018-06-30 | $50.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $45.24M 10-Q · filed 2018-08-03 | $79.18M derived: sum of 3 quarters · filed 2019-05-08 | $112.73M derived: sum of 4 quarters · filed 2019-05-08 | ||
| 2018-03-31 | -$4.90M 10-Q · filed 2019-05-08 | -$4.91M 10-Q · filed 2018-05-04 | $29.05M derived: sum of 2 quarters · filed 2019-05-08 | $62.60M derived: sum of 3 quarters · filed 2019-05-08 | $67.22M derived: sum of 4 quarters · filed 2019-05-08 | |
| 2017-12-31 | $33.95M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $67.50M derived: sum of 2 quarters · filed 2019-02-22 | $72.11M derived: sum of 3 quarters · filed 2019-02-22 | $82.60M 10-K · filed 2019-02-22 | ||
| 2017-09-30 | $33.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | $38.17M derived: sum of 2 quarters · filed 2018-11-02 | $48.65M 10-Q · filed 2018-11-02 | $86.04M derived: sum of 4 quarters · filed 2018-11-02 | ||
| 2017-06-30 | $4.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $15.10M 10-Q · filed 2018-08-03 | $52.49M derived: sum of 3 quarters · filed 2018-08-03 | $73.83M derived: sum of 4 quarters · filed 2018-08-03 | ||
| 2017-03-31 | $10.48M 10-Q · filed 2018-05-04 | $47.88M derived: sum of 2 quarters · filed 2018-05-04 | $69.22M derived: sum of 3 quarters · filed 2018-05-04 | $58.27M derived: sum of 4 quarters · filed 2018-05-04 | ||
| 2016-12-31 | $37.39M 10-K · filed 2018-02-23 | $58.73M derived: sum of 2 quarters · filed 2018-02-23 | $47.78M derived: sum of 3 quarters · filed 2018-02-23 | $51.80M 10-K · filed 2019-02-22 | $51.78M 10-K · filed 2017-02-28 | |
| 2016-09-30 | $21.34M 10-K · filed 2018-02-23 | $10.39M derived: sum of 2 quarters · filed 2018-02-23 | $14.38M 10-Q · filed 2017-11-03 | $47.73M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2016-06-30 | -$10.95M 10-K · filed 2018-02-23 | -$6.96M 10-Q · filed 2017-08-04 | $26.39M derived: sum of 3 quarters · filed 2018-02-23 | $63.33M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2016-03-31 | $3.99M 10-K · filed 2018-02-23 | $37.34M derived: sum of 2 quarters · filed 2018-02-23 | $74.28M derived: sum of 3 quarters · filed 2018-02-23 | $88.38M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2015-12-31 | $33.35M 10-K · filed 2017-02-28 | $70.29M derived: sum of 2 quarters · filed 2017-02-28 | $84.39M derived: sum of 3 quarters · filed 2017-02-28 | $62.87M 10-K · filed 2017-02-28 | ||
| 2015-09-30 | $36.94M 10-K · filed 2017-02-28 | $36.94M 10-Q · filed 2015-11-06 | $51.04M derived: sum of 2 quarters · filed 2017-02-28 | $29.52M 10-Q · filed 2016-11-09 | $59.64M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-06-30 | $14.10M 10-K · filed 2017-02-28 | -$7.42M 10-Q · filed 2016-08-05 | $22.70M derived: sum of 3 quarters · filed 2017-02-28 | $44.53M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-03-31 | -$21.52M 10-K · filed 2017-02-28 | $8.60M derived: sum of 2 quarters · filed 2017-02-28 | $30.43M derived: sum of 3 quarters · filed 2017-02-28 | $35.46M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2014-12-31 | $30.12M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $51.95M derived: sum of 2 quarters · filed 2017-02-28 | $56.98M derived: sum of 3 quarters · filed 2017-02-28 | $36.74M 10-K · filed 2017-02-28 | ||
| 2014-09-30 | $21.83M 10-Q · filed 2015-11-06 | $26.86M derived: sum of 2 quarters · filed 2015-11-06 | $6.63M 10-Q · filed 2015-11-06 | $21.84M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-06-30 | $5.03M 10-Q · filed 2015-08-06 | -$15.21M 10-Q · filed 2015-08-06 | $10.00K derived: sum of 3 quarters · filed 2016-02-29 | $13.50M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-03-31 | -$20.24M 10-Q · filed 2015-05-08 | -$5.02M derived: sum of 2 quarters · filed 2016-02-29 | $8.47M derived: sum of 3 quarters · filed 2016-02-29 | $18.83M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2013-12-31 | $15.22M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $28.71M derived: sum of 2 quarters · filed 2016-02-29 | $39.06M derived: sum of 3 quarters · filed 2016-02-29 | $30.26M 10-K · filed 2016-02-29 | ||
| 2013-09-30 | $13.49M 10-Q · filed 2014-11-10 | $23.85M derived: sum of 2 quarters · filed 2014-11-10 | $15.04M 10-Q · filed 2014-11-10 | $30.04M derived: sum of 4 quarters · filed 2015-03-09 | ||
| 2013-06-30 | $10.36M 10-Q · filed 2014-08-08 | $1.55M 10-Q · filed 2014-08-08 | $16.55M derived: sum of 3 quarters · filed 2015-03-09 | $22.17M derived: sum of 4 quarters · filed 2015-03-09 | ||
| 2013-03-31 | -$8.80M 10-Q · filed 2014-05-12 | $6.20M derived: sum of 2 quarters · filed 2015-03-09 | $11.82M derived: sum of 3 quarters · filed 2015-03-09 | $17.36M derived: sum of 4 quarters · filed 2015-03-09 | ||
| 2012-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $20.62M derived: sum of 2 quarters · filed 2015-03-09 | $26.17M derived: sum of 3 quarters · filed 2015-03-09 | $18.14M 10-K · filed 2015-03-09 | ||
| 2012-09-30 | $5.62M 10-Q · filed 2013-11-08 | $11.17M derived: sum of 2 quarters · filed 2013-11-08 | $3.14M 10-Q · filed 2013-11-08 | $30.04M derived: sum of 4 quarters · filed 2014-03-10 | ||
| 2012-06-30 | $5.55M 10-Q · filed 2013-08-06 | -$2.48M 10-Q · filed 2013-08-06 | $24.42M derived: sum of 3 quarters · filed 2014-03-10 | $24.29M derived: sum of 4 quarters · filed 2014-03-10 | ||
| 2012-03-31 | -$8.02M 10-Q · filed 2013-05-03 | $18.88M derived: sum of 2 quarters · filed 2014-03-10 | $18.74M derived: sum of 3 quarters · filed 2014-03-10 | $31.26M derived: sum of 4 quarters · filed 2014-03-10 | ||
| 2011-12-31 | $26.90M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $26.76M derived: sum of 2 quarters · filed 2014-03-10 | $39.29M derived: sum of 3 quarters · filed 2014-03-10 | $16.11M 10-K · filed 2014-03-10 | ||
| 2011-09-30 | -$137.00K 10-Q · filed 2012-11-01 | $12.39M derived: sum of 2 quarters · filed 2012-11-01 | -$10.79M 10-Q · filed 2012-11-01 | $13.10M derived: sum of 4 quarters · filed 2013-03-08 | ||
| 2011-06-30 | $12.52M 10-Q · filed 2012-08-03 | -$10.65M 10-Q · filed 2012-08-03 | $13.24M derived: sum of 3 quarters · filed 2013-03-08 | $25.18M derived: sum of 4 quarters · filed 2013-03-08 | ||
| 2011-03-31 | -$23.17M 10-Q · filed 2012-05-04 | $715.00K derived: sum of 2 quarters · filed 2013-03-08 | $12.66M derived: sum of 3 quarters · filed 2013-03-08 | $22.09M derived: sum of 4 quarters · filed 2013-03-08 | ||
| 2010-12-31 | $23.89M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08 | $35.83M derived: sum of 2 quarters · filed 2013-03-08 | $45.27M derived: sum of 3 quarters · filed 2013-03-08 | $47.18M 10-K · filed 2013-03-08 | ||
| 2010-09-30 | $11.94M 10-Q · filed 2011-11-04 | $21.38M derived: sum of 2 quarters · filed 2011-11-04 | $23.30M 10-Q · filed 2011-11-04 | |||
| 2010-06-30 | $9.43M 10-Q · filed 2011-08-05 | $11.35M 10-Q · filed 2011-08-05 | ||||
| 2009-12-31 | $26.55M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |